Skip to main content
Download PDF

Effective treatment of metastatic sentinel lymph nodes by dual-targeting melittin nanoparticles

Journal of Nanobiotechnology volume 21, Article number: 245 (2023) Cite this article

Abstract

Sentinel lymph node (SLN) metastasis is an important promoter of distant metastasis in breast cancer. Therefore, the timely diagnosis and precise treatment are crucial for patient staging and prognosis. However, the simultaneous diagnosis of metastasis and the implementation of imaging-guided SLN therapy is challenging. Here, we report a melittin-loaded and hyaluronic acid (HA)-conjugated high-density lipoprotein (HDL) mimic phospholipid scaffold nanoparticle (MLT-HA-HPPS), which dually-target to both breast cancer and its SLN and efficiently inhibit SLN metastasis in the LN metastasis model. The melittin peptide was successfully loaded onto HA-HPPS via electrostatic interactions, and MLT-HA-HPPS possesses effective cytotoxicity for breast cancer 4T1 cells. Moreover, the effective delivery of MLT-HA-HPPS from the primary tumor into SLN is monitored by NIR fluorescence imaging, which greatly benefits the prognosis and treatment of metastatic SLNs. After paracancerous administration, MLT-HA-HPPS can efficiently inhibit primary tumor growth with an inhibition rate of 81.3% and 76.5% relative to the PBS-treated control group and HA-HPPS group, respectively. More importantly, MLT-HA-HPPS can effectively inhibit the growth of the metastatic SLNs with an approximately 78.0%, 79.1%, and 64.2% decrease in SLNs weight than those in PBS, HA-HPPS, and melittin-treated mice, respectively. Taken together, the MLT-HA-HPPS may provide an encouraging theranostic of SLN drug delivery strategy to inhibit primary tumor progression and prevent SLN metastasis of breast cancer.

Graphical Abstract

Introduction

According to the latest Global Cancer Statistics 2020 report, female breast cancer has overtaken lung cancer as the most diagnosed cancer, with an estimated 2.3 million new cases, and both incidence and mortality rates are increasing every year [1, 2]. Malignant tumors have become one of the most important public health issues threatening human health, cancer metastasis is responsible for up to 90% of mortality in breast cancer patients, which is extremely difficult to treat in the clinic [3, 4]. The sentinel lymph node (SLN) is typically the first site reached by malignant cancer cells as they spread through the lymphatic system, where most solid tumors can metastasize [5, 6]. Despite significant advances in the current approach to treating primary tumors, it is not easy to deliver therapeutics to metastatic sites, especially to SLN.

Clinical surgery and radiotherapy are currently the most common methods of treating LN metastases [5]. However, due to the challenges of completely removing metastases with conventional surgery, especially the scattered microscopic foci that are easily missed, and the ineffectiveness of conventional chemotherapy delivery to metastatic regions, there exists a possibility for residual tumor tissue to further develop to distant metastases [7, 8]. In addition, the adverse effects of SLN dissection, which include discomfort, lymphedema, and joint dyskinesia, may affect the patient’s quality of life [9]. Therefore, the development of novel methods to efficiently deliver therapeutics to the SLN, where tumors metastasize, could considerably suppress tumor growth and reduce mortality in cancer patients.

Recently, nanoparticles with targeting probes and drug payloads are expected to overcome this problem by efficiently delivering complex drug molecules to tumor sites to inhibit metastatic tumor progression alone or in combination with other therapies [10,11,12,13,14]. Nanoparticles may therefore offer a new avenue for inhibiting tumor SLN metastasis. J. Wang et al. synthesized iCluster/Pt nanoparticles, which incorporate the chemotherapeutic drug cisplatin (Pt) into the polyamidoamine (PAMAM) nanoparticle. After intravenous administration, iCluster/Pt can first naturally aggregate at the tumor site before depolymerizing into smaller PAMAM that can be transferred to the tumor metastatic SLN and inhibit the growth of 4T1 tumor cells [15]. Cabral and co-workers prepared DACHPt nanomicelles by encapsulating oxaliplatin in polymeric micelles. They observed that DACHPt-containing nanomicelles could preferentially accumulate in SLN and reside in tumors after intravenous injection, thereby effectively suppressing LN metastasis and reducing the incidence of tumor recurrence [16]. These studies have highlighted the importance of LN delivery via systemic administration by utilizing the vascular leakage characteristics of tumors. However, it’s frequently required to increase the drug concentration in the SLN by increasing the administered nanodrug dose, because tumor vascularization is difficult in the early stages of metastasis [17]. In addition, many systemic therapies are associated with toxicities and some may even be prometastatic [18, 19]. Therefore, it remains a great difficulty to use system administration nanoparticles to target tumor cells in the early stages of SLN metastases, and it is of great desire to develop an alternative SLN metastasis delivery strategy that is independent of the metastasis tumor SLN vasculature.

It has been reported that epithelial-derived tumors mainly use tumor lymphatics to disseminate from the primary tumor to LNs [20, 21], by which we are inspired to propose that tumor lymphatics could be an alternative route to deliver tracers or nanotherapeutics to LNs. The efficacy of this pathway has recently been validated by intratumoral or paracancerous injection of nanotherapeutics. For example, C. Liang et al. showed that simultaneous laser irradiation of in situ breast cancer tumors and metastatic LN after intratumoral injection of single-walled carbon nanotubes can successfully suppress cancer metastasis to SLN [22]. By encapsulating the chemotherapeutic drug cyclophosphamide in lipid nanoparticles modified with the cell-penetrating peptide R9 for target breast cancer, H. Hu and co-workers improved the inhibitory effect on primary tumor and tumor SLN metastasis via intratumorally injection of the nanomedicine [23]. However, these studies may still have some shortcomings. Firstly, after intratumorally injection, the nanoparticles are mainly taken up by antigen-presenting cells (APCs) and thus alleviate the efficiency to target and eradicate metastatic tumor cells in the SLN. Additionally, these nanoparticles lack an inherent diagnostic capability to accurately determine whether SLN metastasis has occurred. Therefore, there is an urgent need to develop a multifunctional nanoprobe that can efficiently identify the tumor metastatic status of the SLN while also directly targeting and eradicating metastatic cancer cells in the SLN.

Melittin, a natural cationic host defense peptide consisting of 26 amino acid residues (GIGAVLKVLTTGLPALISWIKRKRQQ) derived from bee venom, possesses tumor cell cytotoxicity and immunomodulatory functions [24, 25]. With its strong positive charge properties, melittin can interact with biological membranes and disrupt their integrity by forming transmembrane pores, which can directly induce tumor cell apoptosis or necrosis [26]. However, the in vivo applications of this peptide are limited due to the side effect of hemolysis after intravenous injection. Previously, we developed a high-density lipoprotein (HDL)-mimicking peptide-phospholipid scaffold (named HPPS), whose structure could be precisely controlled by an α-helical peptide [27]. Subsequently, we designed a hybrid peptide based on α-helical peptide and successfully loaded melittin onto the scaffold to form a melittin-lipid nanoparticle, which effectively shielded the positive charge of melittin within the phospholipid monolayer, resulting in reduced hemolysis [28,29,30]. Recently, we developed a CD44 and scavenger receptor class B1 (SR-B1) dual-targeted hyaluronic acid (HA) conjugated HDL mimic phospholipid scaffold nanoparticle (HA-HPPS) with fluorescence/photoacoustic dual-modal imaging capability [31]. Our results confirmed that HA-HPPS effectively targets metastatic 4T1 cells in SLN, and HA-HPPS combined with photoacoustic microscopy imaging can distinguish 4T1 cells metastatic SLN from inflamed and normal LNs. Therefore, in this proof-of-concept study (Scheme 1), we hypothesize that HA-HPPS loaded with the cytolytic melittin peptide, which has a direct tumor killing function, could effectively inhibit the growth of primary breast cancer as well as the metastasis of tumor cells in SLN. In this study, the melittin peptide was successfully loaded onto dual-targeted HA-HPPS nanoparticles via electrostatic interactions, and the melittin loaded HA-HPPS nanoparticles (donated as MLT-HA-HPPS) possess effective cytotoxicity for 4T1 cells. MLT-HA-HPPS exhibit the ability to target tumor SLN and inhibit primary tumor growth and SLN metastasis, thus offering a promising therapeutic approach for the clinical treatment of SLN metastasis in breast cancer.

Scheme 1
scheme 1

(a) Components and structures of the CD44 and SR-B1 dual-targeting HA-HPPS and MLT-HA-HPPS nanoparticles. (b) Growth inhibition of breast cancer SLN metastasis by melittin-loaded MLT-HA-HPPS

Full size image

Results

Characterization of MLT-HA-HPPS in vitro

Based on our pre-developed dual-targeted HA-HPPS nanoparticles (Scheme 1a) with negative charges, the positively charged cytolytic melittin should be able to bind to HA-HPPS through electrostatic effects. Therefore, to determine the appropriate amount of melittin added to HA-HPPS, we first optimized the amount of melittin for the synthesis of melittin-loaded dual-targeted MLT-HA-HPPS. The method used to synthesize HA-HPPS was reported in our previous study [31]. After the synthesis of HA-HPPS nanoparticles, different amounts of melittin were added to the purified HA-HPPS solution and stored overnight at 4℃. After ultrafiltration, the content of melittin peptide, the size, and zeta potential on MLT-HA-HPPS were examined. The results in Table 1 shown that MLT-HA-HPPS was loaded with 0.076 ± 0.009 μmol and 0.043 ± 0.014 μmol of melittin when adding 0.18 μmol and 0.36 μmol of melittin in HA-HPPS, respectively. This result indicated that the melittin had been successfully loaded onto the HA-HPPS by the electrostatic effect. Dynamic light scattering (DLS) measurement results indicated that the MLT-HA-HPPS showed a size of 41. 2 ± 2.1 nm (0.18 μmol melittin) and 45.1 ± 2.8 nm (0.36 μmol melittin), respectively, which were not significantly different from that of HA-HPPS (43.5 ± 1.8 nm) (Fig. 1a, b). The suitable size (< 100 nm) of the MLT-HA-HPPS should be appropriate for lymphatic delivery [32]. In addition, the zeta potential profiles indicated that HA-HPPS carried a negative charge (− 6.18 ± 1.61 mV) and melittin carried positive charges (15.17 ± 2.52 mV) (Fig. 1c). However, after loading with melittin, the MLT-HA-HPPS presented positive charges, but the charge of 0.18 μmol melittin MLT-HA-HPPS (10.53 ± 0.57 mV) was higher than that of 0.36 μmol melittin MLT-HA-HPPS (6.27 ± 0.41 mV) (Fig. 1d), it can be inferred that the MLT-HA-HPPS with 0.18 μmol melittin bound more of the substance. Transmission electron microscopy (TEM) result clearly showed that HA-HPPS and MLT-HA-HPPS (0.18 μmol melittin) had uniform spherical morphologies and similar particle size (Fig. 1d). To verify the stability of MLT-HA-HPPS, we initially assessed how the size and zeta potential of the MLT-HA-HPPS hydrate changed before and after lyophilization and rehydration. Our results indicated that the MLT-HA-HPPS hydrate could be easily lyophilized and then rehydrated, if necessary, while the size and zeta potential of the MLT-HA-HPPS were not significantly changed (Additional file 1: Fig. S1a, b). In addition, semi-native SDS–polyacrylamide gel electrophoresis (SDS-PAGE) and fluorescence imaging showed that the dual-labeled MLT-HA-HPPS with fluorescein isothiocyanate (FITC) and DiR-BOA was still stable in the 10% FBS and 10% plasma even for 24 h at 37 °C, as both the FITC and DiR-BOA fluorescence signals were detectable in the same band (Additional file 1: Fig. S1c), whereas incubation with 10% Triton-X 100 disrupted the structure of MLT-HA-HPPS and showed unrestricted diffusion of FITC and DiR-BOA fluorescence signals. The UV–Vis absorption spectrum showed that MLT-HA-HPPS and HA-HPPS had obvious enhancement peaks at 280 nm (peptide) and 750 nm (DiR-BOA), respectively, whereas the characteristic absorption peak of MLT-HA-HPPS at 280 nm was slightly stronger than that of HA-HPPS with the same molar content of R4F peptide (Additional file 1: Fig. S2), this may be attributed to the loaded melittin on MLT-HA-HPPS. The peptide release profiles are shown in Additional file 1: Fig. S6, and nearly 45% of the total peptide was released from MLT-HA-HPPS after 96 h of dialysis in PBS solution at room temperature. Meanwhile, about 10% and 54% of free melittin leaked out after 3 h and 24 h of dialysis, respectively. Above all, these data suggested that the melittin was successfully loaded onto MLT-HA-HPPS via electrostatic effects with a size of nearly 40 nm and carrying positive charges.

Table 1 Characterization of dual-targeted nanoparticles with different amount of melittin
Full size table
Fig. 1
figure 1

Characterization of dual-targeted nanoparticles. (a) The size distribution of different contents (0.18 μmol and 0.36 μmol) of melittin-loaded dual-targeted nanoparticles by using dynamic light scattering (DLS). (b) Quantitative analysis of the DLS size data derived from (a). (c) The zeta potential of HA-HPPS, free melittin, and MLT-HA-HPPS with different melittin contents tested in water solvent. (d) TEM image of HA-HPPS and MLT-HA-HPPS. Data are presented as the mean ± SD, Scale bar: 50 nm. n = 3. ***P < 0.001

Full size image

In vitro evaluation of cellular uptake and cytotoxicity of MLT-HA-HPPS to 4T1 cells

After synthesizing the melittin-loaded dual-targeted MLT-HA-HPPS, we first verified their ability to target breast cancer 4T1 cells, which highly expressed SR-B1 and CD44 receptors [33, 34]. Nanoparticles with different concentrations of DiR-BOA (0.3125, 0.625, 1.25, 2.5, 5, 10, and 20 μM) were incubated with 4T1 cells for 0.5 h, 1 h, and 3 h, respectively, and the intracellular signal intensity was measured by flow cytometry (FCM) and confocal imaging. The FCM results showed that 4T1 cells took up nanoparticles in a concentration and time-dependent manners, the mean fluorescence intensity (MFI) of DiR-BOA in 4T1 cells incubated with MLT-HA-HPPS was much stronger than that of HA-HPPS, with 1.7 times (0.5 h), 1.5 times (1 h), and 1.6 times (3 h) difference at a high concentration of DiR-BOA (20 μM) (Fig. 2a), respectively. In addition, confocal imaging results also clearly showed that the fluorescence signal intensity in 4T1 cells treated with MLT-HA-HPPS was much stronger than that of HA-HPPS after 1 h of incubation (Fig. 2b). These results indicated that the ability of MLT-HA-HPPS to target 4T1 cells was significantly improved by the addition of melittin, thus providing a suitable candidate for its capacity to destroy tumor cells and prevent their metastasis to LN in vivo. Melittin has a strong ability to kill tumor cells through disrupting the phospholipid bilayer of cell membranes by forming transmembrane pores. Therefore, we further assessed the cytotoxicity of MLT-HA-HPPS in tumor cells by comparing the half-maximal inhibitory concentration (IC50) of melittin and MLT-HA-HPPS. The cell survival results showed that within the incubation concentrations, HA-HPPS had essentially no effect on tumor cell survival (Fig. 2c), compared with the IC50 of free melittin (2.66 ± 0.09 μM), MLT-HA-HPPS appeared to decrease the cytotoxicity on tumor cells at 3 h, as indicated by an increased IC50 value of 5.21 ± 0.13 μM, suggesting that the toxicity of melittin was partially shielded by the phospholipid layer and HA molecules after melittin was loaded onto the dual-targeted nanoparticles. However, when the incubation time of MLT-HA-HPPS with 4T1 cells was prolonged for 6 h and 12 h, the cytotoxicity of MLT-HA-HPPS was stronger than that of free melittin (Additional file 1: Fig. S3), with a decreased IC50 of MLT-HA-HPPS (1.21 ± 0.11 and 0.86 ± 0.08 μM) compared to free melittin (2.12 ± 0.15 and 1.38 ± 0.07 μM) for 6 h and 12 h, respectively. The enhanced cytotoxicity of MLT-HA-HPPS for 4T1 cells may be due to the slow release of melittin on MLT-HA-HPPS with a longer incubation time and may also be related to the targeting ability of MLT-HA-HPPS for 4T1 cells. Finally, we investigated the time- and concentration-dependent cytotoxicity of MLT-HA-HPPS against tumor cells and the mechanism underlying cell death. 4T1 cells were treated with 2.5 μM and 10 μM melittin of MLT-HA-HPPS for different times and then stained with Annexin V-FITC/PI for FCM analysis. As shown in Fig. 2d, the percentage of tumor cell death gradually increased with increasing incubation time. Low concentrations (2.5 μM) of MLT-HA-HPPS induced both early apoptosis (lower-right quadrant) and necrosis (upper-right quadrant) in 4T1 cells, while high concentrations (10 μM) of MLT-HA-HPPS primarily resulted in 4T1 cells necrosis (82.7%) (upper-right quadrant). These above results indicated that MLT-HA-HPPS not only exerts an enhanced ability to target 4T1 cells, but also has greater cytotoxicity to induce cell apoptosis and necrosis.

Fig. 2
figure 2

In vitro evaluation of cellular uptake and cytotoxicity of MLT-HA-HPPS to 4T1 cells. (a) Flow cytometry (FCM) was performed to analyze and compare uptake of HA-HPPS and MLT-HA-HPPS by 4T1 cells in vitro after exposure to various concentrations for 0.5 h, 1 h, and 3 h. (b) Confocal imaging was performed to compare 4T1 cell uptake of HA-HPPS and MLT-HA-HPPS in vitro after exposure to DiR-BOA (10 μM) for 1 h incubation. (c) Proliferation assays evaluating the cytotoxicity of melittin, HA-HPPS, and MLT-HA-HPPS on 4T1 cells for 3 h. (d) Scatter plot of the FCM assays examining the cytotoxicity of MLT-HA-HPPS in 4T1 cells at different time and concentrations. Data are presented as the mean ± SD. n = 3. **P < 0.01, ***P < 0.001

Full size image

In vivo tracking of HA-HPPS and MLT-HA-HPPS to target normal popliteal LN

In our previous study, we demonstrated the target ability of HA-HPPS in normal LNs [31]. Therefore, we speculated that the MLT-HA-HPPS might also be able to target normal LN. To verify this, DiR-BOA labeled MLT-HA-HPPS and HA-HPPS were subcutaneously injected into the footpad of normal mice, and the fluorescence signals in the normal popliteal LN (PLN) were dynamically monitored at 1, 3, 6, 12, and 24 h. As shown in Fig. 3a, the PLNs of the MLT-HA-HPPS group showed a strong DiR-BOA fluorescence signal equal to that of the HA-HPPS group at 1 h, and the fluorescence signals remained detectable up to 24 h. To further confirm the LN targeting ability of MLH-HA-HPPS, we dissected the ipsilateral PLN (iPLN) and contralateral PLN (cPLN) of mice at 24 h post-injection. The in vitro imaging results showed that both the iPLN of the MLT-HA-HPPS and HA-HPPS groups showed stronger fluorescence signals rather than the cPLN (Fig. 3b, c). In addition, in vitro organ fluorescence imaging showed that HA-HPPS was mainly distributed in the liver, spleen, lung, kidney, and iPLN after 24 h footpad injection of nanoparticles, while MLT-HA-HPPS was mainly distributed in the liver, lung, and iPLN (Fig. 3b, c). Furthermore, the immunofluorescence imaging of iPLN showed that the MLT-HA-HPSS and HA-HPPS were mainly taken up by macrophages (F4/80+) and dendritic cells (DC) (CD11c+) (Additional file 1: Fig. S4). Thus, these results suggested that MLT-HA-HPPS can effectively target LNs after subcutaneous injection. Finally, we tested the in vivo adverse effects of nanoparticles, the functional markers of both the liver (ALT, AST, and TBIL) and kidney (BUN) were distributed in the normal range after 24 h and 48 h nanoparticles injection (Additional file 1: Fig. S5a). Meanwhile, the pathological examination of the major organs (heart, liver, kidney, spleen, lung, brain, and iPLN) by hematoxylin–eosin (H&E) staining suggested that there was no obvious organ damage or tissue denaturation for HA-HPPS and MLT-HA-HPPS treatment compared to normal mouse organs (Additional file 1: Fig. S5b). Thus, the above results suggest that MLT-HA-HPPS can effectively target LNs after subcutaneous injection while maintaining great biosafety.

Fig. 3
figure 3

In vivo tracking of HA-HPPS and MLT-HA-HPPS to target normal popliteal LN. a Fluorescence imaging of the target ability of HA-HPPS and MLT-HA-HPPS in normal popliteal LNs (PLN) at 1, 3, 6, 12, and 24 h after footpad injection. b Representative fluorescence imaging of the dissected organs and LNs after 24 h footpad injection. c Quantitative analysis of the MFI of DiR-BOA in the organs and PLNs (n = 3 per group). iPLN ipsilateral popliteal LN, cPLN contralateral popliteal LN

Full size image

In vivo comparisons of the migratory capabilities of HA-HPPS and MLT-HA-HPPS to popliteal SLN

After verifying the cytotoxicity of MLT-HA-HPPS against tumor cells in vitro, we next tested the ability of MLT-HA-HPPS to migrate to tumor metastatic SLN and target 4T1 cells in vivo. Six days after inoculation of 4T1 cells into both hocks of BALB/c mice, MLT-HA-HPPS and HA-HPPS were paracancer injected into the hocks area (Fig. 4a), and fluorescence imaging was performed to dynamically monitor the fluorescence signal intensity in the popliteal SLN (pSLN) at different time points. As shown in Fig. 4b, the signals of MLT-HA-HPPS and HA-HPPS could be detected in the pSLN as early as 0.5 h after injection, and the fluorescence signal reached its strongest at 6 h (Fig. 4b). Quantitative analysis of the mean fluorescence intensity (MFI) of pSLN showed that the MFI of pSLN in the HA-HPPS group was greater than that in the MLT-HA-HPPS group, but there was no significant difference between them except at 24 h (Fig. 4c).

Fig. 4
figure 4

In vivo comparisons of the migratory capabilities of HA-HPPS and MLT-HA-HPPS to popliteal SLN. a Schematic of popliteal SLN (pSLN) tumor metastasis detection after six days of 4T1 cells inoculation. b Representative fluorescence images to observe the migratory capabilities of HA-HPPS and MLT-HA-HPPS to pSLN at 0.5, 3, 6, 12, and 24 h after paracancer injection. c Quantitative analysis of the MFI of DiR-BOA in pSLN. d Six days after hock inoculation of tfRFP-4T1 cells (1 × 106 cells/mouse), fluorescence imaging of resected pSLNs were performed at 6 h after paracancer injection of FITC-labelled HA-HPPS and MLT-HA-HPPS. Red: tfRFP-4T1 cells, green: FITC-labelled nanoparticles. e Quantitative analysis of the MFI of FITC on resected pSLNs. f Confocal microscopy verified the ability of FITC-labelled HA-HPPS and MLT-HA-HPPS to target 4T1 cells in tumor metastasis SLNs. Blue: DAPI, Red: tfRFP-4T1 cells, green: FITC-labelled HA-HPPS and MLT-HA-HPPS. Data are presented as the mean ± SD. n = 3 mice/group. *P < 0.05

Full size image

Finally, the in vivo abilities of HA-HPPS and MLT-HA-HPPS to target 4T1 cells were examined in a tumor metastatic SLN model, which was established by hock inoculation of a tetrameric far-red fluorescent protein-labelled 4T1 cells (tfRFP-4T1 cells) into the legs of BALB/c mice. Six days after tumor inoculation, FITC-labelled nanoparticles were injected paracancerously into the primary tumors and pSLNs were harvested 6 h later. Fluorescence imaging showed that pSLNs had bright fluorescence signals of both the tfRFP protein and FITC (Fig. 4d), indicating that the tfRFP-4T1 cells metastasized and nanoparticles accumulated in the SLNs. A similar MFI of FITC was observed between MLT-HA-HPPS and HA-HPPS in the quantitative analysis of resected pSLNs (Fig. 4e). Confocal imaging of pSLN sections showed that a large number of tfRFP-4T1 cells appeared in the mice with tumor metastatic SLNs. More importantly, both FITC-labelled HA-HPPS and MLT-HA-HPPS were colocalized with most of the tfRFP-4T1 cells in SLNs (Fig. 4f). These above results indicated that MLT-HA-HPPS could not only efficiently migrate to the pSLN like HA-HPPS, but also effectively target 4T1 cells in vivo, thus providing an effective tool for delivering melittin to the tumor SLN.

MLT-HA-HPPS effective in inhibiting breast cancer growth in vivo

Having demonstrated the ability of MLT-HA-HPPS to effectively kill tumor cells and target SLN, we next investigated the ability of MLT-HA-HPPS to inhibit breast cancer growth and SLN metastasis in vivo, which is a LN metastasis tumor model established by hock inoculation of tfRFP-4T1 cells into the right legs of BALB/c mice. On days 2, 4, and 6 after tumor inoculation, the mice were treated with paracancerous injections of 20 nmol peptide of HA-HPPS, melittin, and MLT-HA-HPPS in PBS, with a total volume of 40 μL, while equal volume of sterile PBS was injected as a control group. The changes in hock tumor volumes and body weight of the mice were continuously monitored on different days. The tumor growth curve showed that MLT-HA-HPPS dramatically suppressed tumor growth on the right legs (Fig. 5a). Compared with the tumor volume of the PBS group (125.1 ± 30.1 mm3), mice treated with HA-HPPS (121.2 ± 7.7 mm3) had no effect on tumor growth 14 days after tumor inoculation. Interestingly, mice treated with melittin and MLT-HA-HPPS were able to significantly inhibit the hock tumors growth, while MLT-HA-HPPS (34.5 ± 9.0 mm3) showed more excellent ability to suppress tumor growth compared to the melittin group (77.5 ± 10.3 mm3). Both the in vivo images of mice (Fig. 5b) and the in vitro image (Fig. 5c) and weights of the resected tumors further confirmed the significantly efficient inhibition of tumor growth by MLT-HA-HPPS (39.6 ± 21.5 mg), with an inhibition rate of 81.3% and 76.5% relative to the PBS-treated control group (210.9 ± 80.0 mg) and HA-HPPS group (168.7 ± 27.5 mg), respectively (Fig. 5d). Although, the weights of tumors in the melittin group (120.1 ± 27.1 mg) were lighter than those in the PBS and HA-HPPS groups, there were no significant difference between them. In addition, it is worth mentioning that there were no differences in the body weight of tumor-bearing mice during the treatment period (Fig. 5e), leading to the preliminary conclusion that MLT-HA-HPPS had no remarkable toxic effects on mice after paracancer administration. These results indicated that the melittin-loaded dual-targeted MLT-HA-HPPS carrying melittin possessed the ability to significantly inhibit breast tumor growth in vivo while maintaining high biocompatibility via paracancer administration.

Fig. 5
figure 5

In vivo evaluations of the inhibition effect of MLT-HA-HPPS on the breast cancer growth. a Tumor volume curves of 4T1 tumors in each group with three times paracancer injection after 2 days of hock inoculation tfRFP-4T1 cells. Tumor volume in the MLT-HA-HPPS-treated group was significantly inhibited compared to the other groups. b In vivo mice photographs and c Ex vivo tumors from each group on the 14th day. d Quantitative analysis of tumor weight in different groups. 3–4 mice/group. e Changes in body weight of mice during treatment. Data are shown as the mean ± SD. ns means not significant. *P < 0.05, **P < 0.01, ***P < 0.001

Full size image

Growth inhibition of breast cancer SLN metastasis

Encouraged by their efficient therapeutic effect on the primary tumor, we finally explored the application of MLT-HA-HPPS in the treating of cancer LN metastasis, taking advantage of its potent LN accumulation capacity. The mice were sacrificed and the metastatic pSLNs were harvested and weighed at the end of the antitumor activity study. The photographs of the resected pSLNs in Fig. 6a showed that the PBS, HA-HPPS, and melittin control groups showed significantly swollen pSLNs, indicating severe lymphatic enlargement due to cancer cell migration and proliferation. In contrast, treatment with MLT-HA-HPPS resulted in the smallest size and weight of pSLNs compared to controls and comparable to normal LNs. Although the average weights of the pSLNs in MLT-HA-HPPS-treated mice (4.8 ± 3.1 mg) were 1.67fold higher than normal LNs (1.8 ± 0.8 mg, P = 0.11), they were significantly decreased by 78.0%, 79.1%, and 64.2% than those in PBS treated control mice (21. 8 ± 2.8 mg), HA-HPPS-treated mice (23.0 ± 2.6 mg), and melittin-treated mice (13.4 ± 2.5 mg), respectively (Fig. 6b), indicating that MLT-HA-HPPS effectively inhibited SLN metastasis. Next, ex vivo fluorescence imaging was performed on the harvested pSLN to evaluate the extent of tumor metastasis from different treatment groups. As shown in Fig. 6c, the fluorescence signal of tfRFP-4T1 in the pSLN of the MLT-HA-HPPS group was slightly stronger than the background signal of normal LNs (P = 0.44), but considerably weaker than that in the PBS, HA-HPPS, and melittin groups. Attractively, the fluorescence signal of 4T1-tfRFP was barely detectable in half (2/4) of the pSLN in the MLT-HA-HPPS-treated group, which was significantly weaker than that in the other treatment groups. Although the MFI in the melittin group was much weaker than that in the PBS control group and HA-HPPS group, there was no significant difference between them (Fig. 6d). The confocal imaging of SLN sections showed that many tfRFP-4T1 cells could be detected in PBS, HA-HPPS, and melittin groups, whereas the MLT-HA-HPPS treated SLN contained only a limited number of tfRFP-4T1 tumor cells (Fig. 6e). These results suggested that MLT-HA-HPPS can effectively prevent breast cancer cells from metastasizing to SLN in addition to inhibiting the growth of breast cancer in situ. Thus, it offers a potentially valuable therapeutic tool for the diagnosis and treatment of breast cancer LN metastasis.

Fig. 6
figure 6

In vivo evaluations of the effect of MLT-HA-HPPS on breast cancer SLN metastasis. a Photos of SLN in different groups after 14 days of treatment. b Quantitative analysis of SLN weight in different groups. c–d Ex vivo fluorescence imaging and quantitative analyze the MFI of each group of resected SLNs after 14 days of tumor treatment. Scale bar: 3 mm. e Confocal imaging detects tfRFP-4T1 tumor cells in different group of SLNs. Blue: DAPI, Red: tfRFP-4T1. Scale bar: 500 μm. Data are shown as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001

Full size image

Discussion

Metastasis of tumor cells to distal organs is the major cause of death in cancer patients, and epithelial-origin tumors mainly metastasize to distal organs through the lymphatic system, such as breast cancer and melanoma [20, 21]. Tumor cells detached from the tumor in situ first migrate through lymphatic vessels to the SLN and followed metastasize to the distal organs. Surgical resection and radiotherapy are still the main clinical modalities for the treatment of tumor LN metastases. Nanocolloids labeled with the radioactive element technetium (99mTc) and blue dye are injected around tumors in the breast to identify the location of SLN, which are then removed and sent for histologic examination. Although this method has proven to be clinically effective, the procedure still has some limitations [35]. In our previous study, we developed a CD44 and SR-B1 dual-targeted fluorescence/photoacoustic nanoprobe HA-HPPS, which can accurately differentiate tumor metastatic SLN from normal LN and inflammatory LN by photoacoustic imaging [31], thus providing an effective tool to identify the metastatic status of tumor SLN. Based on these results, we hypothesize that by carrying tumor-killing drugs, MLT-HA-HPPS not only can be used to identify the metastatic status of tumor SLN, but also effectively inhibit the primary tumor metastasis to SLN. It’s been reported that melittin induces TNBC and HER2-enriched breast cancer death by interfering with growth factor-dependent receptor tyrosine kinase (RTK) interactions critical for receptor phosphorylation and suppressing activation of PI3K/Akt signaling [36, 37]. Therefore, we speculate that the potential suppression mechanism of tumor growth in the present study may be related to the inhibition of RTK and PI3K/Akt pathways.

In this study, we combined melittin peptide with HA-HPPS by electrostatic effect to develop a melittin-loaded dual-targeted MLT-HA-HPPS that has integrated diagnosis and treatment of tumor SLN metastasis. This method of loading melittin by electrostatic effect has the characteristics of simple preparation and operation, in addition, the intra-tumoral/paracancerous injection greatly reduce the amount of injected dose, which can effectively decrease the cost and showed great tumor growth inhibition effect. Our fluorescence imaging results showed that HA-HPPS could effectively label tumor metastatic SLN after paracancerous injection, which is consistent with our previous results [31]. Although the effect of MLT-HA-HPPS in labeling the SLN was slightly weaker than that of HA-HPPS, there was no significant difference within 12 h (Fig. 4b, c). We speculated that the reason for this phenomenon might be related to the positive charge carried on the surface of MLT-HA-HPPS. It has been reported that partially negatively charged nanoparticles have the greatest potential for interstitial transfer to the lymphatic system, because the extracellular matrix of tissues is mainly composed of negatively charged glycosaminoglycans [38]. In contrast, since melittin carries a strong positive charge, the surface of MLT-HA-HPPS shows a positive charge when melittin binds to with negatively charged HA-HPPS (Fig. 1c), which favors accumulation at the injection site and limits its ability to migrate to the SLN.

As a host defense peptide, melittin possesses both direct killing of tumor cells and immunomodulatory functions. However, very low concentrations of melittin can induce hemolytic side effects after intravenous injection, which severely limits in vivo applications. Many efforts have been made to modify the melittin sequence to reduce the hemolysis [39,40,41]. C. Huang et al. developed an ultra-small size of melittin nanoparticles (α-melittin-NP) [28], α-melittin-NP can not only be effectively shielded the hemolytic properties by the phospholipid layer, but also has a great ability to directly kill melanoma cells, specifically activate liver sinusoidal endothelial cells and APCs in LNs [29, 30]. In this study, we found that MLT-HA-HPPS (IC50 = 5.21 ± 0.13 μM) had a weaker ability to kill 4T1 cells compared to free melittin (IC50 = 2.66 ± 0.09 μM) (Fig. 2c). We speculated that the strong positive charge of melittin was neutralized by the negatively charged HA-HPPS. In addition, when the melittin interacted with the phospholipid layer of the nanoparticles, which could embed into the phospholipid layer, thus shielding the positive charge of the melittin to reduce the cytotoxicity of the nanoparticles.

Traditional surgical resection of tumors often leads to tumor recurrence and metastasis, and chemotherapy drugs have difficulty reaching microscopic tumor sites. Therefore, the treatment of patients with metastatic tumors is extremely challenging. Currently, researchers have developed various nanodrugs to inhibit primary tumor growth and tumor SLN metastasis with favorable therapeutic effects [42,43,44]. However, these nanodrugs are mainly taken up by APCs, and it is difficult for the nanodrugs to act directly on the tumor cells, which may have potential toxic effects on the immune cells in the LN. Therefore, a more ideal way for nanoparticles is to be able to act directly on metastatic tumor cells for the treatment of tumor metastatic SLN. Recently, X. Wang et al. prepared a targeted nanoprobe using TMVP1-modified polymer nanomaterials for tumor metastasis SLN imaging and performed imaging-guided photothermal therapy [45]. G. Zhang et al. developed a Cel-loaded erythrocyte-derived microvesicle functionalized with R4F peptide, which showed selective targeting and killing of SR-B1+ 4T1 tumor cells and induced T cell-mediated systemic antitumor immune responses in the LN metastatic mode of breast cancer [46]. However, although they all achieved better antitumor effects, dual-targeting melittin nanoparticles may have a more potent antitumor effect than single-targeting nanomedicine strategies. It has been reported that 4T1 cell highly express SR-B1 and CD44 receptors [33, 34]. Our previous study demonstrated that 4T1 cells treated with dual-targeted SR-B1 and CD44 HA-HPPS nanoparticles exhibited enhanced uptake compared to single-targeted nanoparticles [31]. In the current study, we found that dual-targeted SR-B1 and CD44 HA-HPPS and MLT-HA-HPPPS could not only effectively target 4T1 cells in vitro (Fig. 2a, b), but also target 4T1 cells in metastatic SLN in vivo (Fig. 4f). Interestingly, the in vitro results showed that MLT-HA-HPPS carrying melittin had an enhanced targeting effect for 4T1 tumor cells. This may be contribution to the fact that the membrane-disrupting function of melittin and MLT-HA-HPPS carries a positive charge. Since negatively charged phosphatidylserine and O-glycosylated mucin are overexpressed in the plasma membrane of many cancer cells, which results in a slightly higher net negative charge in these cell membranes than in normal eukaryotic cells [47]. Furthermore, our previous results found that the different charges on the surface of tumor cell membranes and APC resulted in the different ability of α-melittin-NP to target and kill these cells [30]. Compared with intravenous injection of nanoparticles, intratumoral or paracancerous injection is more likely to accumulate in the tumor metastasis SLN and minimize the toxic side effects to the organs. Our in vivo therapy results showed that MLT-HA-HPPS treatment significantly inhibited both primary tumor growth and SLN metastasis, while melittin also partially inhibited tumor SLN metastasis (Figs. 5a, 6a), demonstrating the ability of melittin to directly kill tumor cells. In addition, the NIR dye DiR-BOA loaded in the core of the nanoparticles has strong light absorption ability [48], so it is possible to combine photothermal therapy with MLT-HA-HPPS to achieve enhanced inhibition of SLN and distant organs metastasis in the future.

Conclusions

In conclusion, we developed a CD44 and SR-B1 receptors dual-targeting lipid nanoparticle loaded with melittin, which effectively inhibited primary tumor growth and SLN metastasis. The melittin binds to HA-HPPS via electrostatic effect and its cytotoxicity is successfully shielded within MLT-HA-HPPS, showing excellent suppressed cellular proliferation ability by inducing tumor cell apoptosis and necrosis. Furthermore, our results showed that paracancer injection of MLT-HA-HPPS not only was able to efficiently migrate to the SLN and target the metastatic tumor cells in the SLN, but also significantly inhibited both primary tumor growth and SLN metastasis in vivo. Thus, the above experimental evidence indicated that MLT-HA-HPPS offers a promising therapeutic approach for the clinical treatment of SLN metastasis in breast cancer due to its enhanced tumor cellular uptake and pronounced therapeutic effects.

Methods

Materials

1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE), 1,2-distearoyl-sn-glycero -3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt) (DSPE-PEG2000, ammonium salt) and 1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC) were obtained from Avanti Polar Lipids Inc (Alabaster, AL, USA). 5 kDa hyaluronic acids (HA) was obtained from Lifecore Biomedical LLC (MN, USA) (cat#: HA5K-1). Fluorescein isothiocyanate (FITC) was purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). R4F (an ApoA1-mimetic peptide, Ac-FAEKFKEAVKDYFA- KFWD) and melittin peptide (GIGAVLKVLTTGLPALISWIKRKRQQ-NH2) were synthesized by Shanghai Apeptide Co., Ltd. (Shanghai, China). The NIR dye DiR-BOA (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbo-cyanine iodide bis-oleate) was synthesized as previously described [49].

Mice and cells

BALB/c female mice were purchased from Changsha Hunan Silaike Jingda Laboratory Animal Co., Ltd. (Changsha, Hunan, China). All animal studies were conducted in compliance with protocols that had been approved by the Hubei Provincial Animal Care and Use Committee (2019S2044) and were performed in compliance with the experimental guidelines of the Animal Experimentation Ethics Committee of Huazhong University of Science and Technology. The mouse mammary adenocarcinoma 4T1 cell line was kindly provided by Professor Li Su (Huazhong University of Science and Technology). tfRFP-4T1 cells were obtained by transfecting 4T1 cells with a plasmid containing the tfRFP gene [50]. These cells were cultured in complete RPMI-1640 medium (Gibco, Thermo Fisher Scientific, USA) containing 10% fetal bovine serum (FBS, Gibco) and 1% penicillin–streptomycin (Gibco) in a cell incubator (Thermo, USA) with 5% CO2 and 95% air at 37 °C.

Synthesis and characterization of the HA-HPPS and MLT-HA-HPPS

The HA-DMPE compound and HA-HPPS synthesized as described in our previously study [31]. Briefly, DMPC (3 μmol), DSPE-PEG2000 (0.0114 μmol), cholesterol oleate (C.O, 0.1 μmol), DiR-BOA (0.2 μmol), and HA-DMPE (5kDa, 0.04 μmol HA) in chloroform (400 μL) were dried under a nitrogen stream. Then, 4 mL of PBS solution was added to the dried film and vortexed for 5 min. Subsequently, the mixture was sonicated for ~ 1 h at 48 °C and R4F (0.78 μmol) was added dropwise to the lipid emulsion, and stored overnight at 4 °C. After concentration using centrifugal filter units (30 kDa, Millipore, USA), the HA-HPPS was purified using the Akta FPLC system with a HiLoad 16/70 Superose 6 column (General Electric Healthcare, NY, USA). For the synthesis of MLT-HA-HPPS, the different concentrations of melittin (0.18 μmol and 0.36 μmol) were added to the HA-HPPS nanoparticle and stored at 4 °C overnight, and the MLT-HA-HPPS was purified using ultrafiltration. The peptide concentration was measured using a Pierce Modified Lowry Protein Assay Kit (Thermo Fisher Scientific; Rockford, IL, USA). The size distributions and morphologies of the nanoparticles were measured by DLS on a Zetasizer Nano-ZS90 (Malvern Instruments, Worcestershire, UK) and TEM (TECNAI G2, FEI Company, OR, USA) respectively.

Confocal imaging and flow cytometry analysis

For confocal imaging, 4T1 cells were seeded (2 × 104 cells/well) into 8-well chambers covering the glass bottoms (Nunc Lab-Tek, Thermo Scientific). The cells were then incubated with HA-HPPS and MLT-HA-HPPS at a DiR-BOA concentration of 10 μM for 1 h, and Hoechst 33258 (0.5 μg mL−1) was added 15 min before washing. Fluorescence images were captured using a laser confocal scanning microscope LSM 710 (Zeiss, Germany) with an excitation wavelength of 405 nm for Hoechst 33258 and DAPI, 488 nm for FITC, and 633 nm for DiR-BOA.

For FCM analysis 4T1 cellular uptake test, 4T1 cells were seeded into 24-well plates (5 × 104 cells/well), and HA-HPPS and MLT-HA-HPPS were incubated with the cells at different DiR-BOA concentrations (0.312, 0.625, 1.25, 2.5, 5, 10, and 20 μM) for 0.5 h, 1 h, and 3 h. An Annexin V-FITC/PI apoptosis detection kit (Vazyme Co., Ltd., Nanjing, China) was used to determine the mechanism of MLT-HA-HPPS-induced cell death. Briefly, 4T1 cells were seeded into 24-well plates (5 × 104 cells/well), the cells were harvested after incubation with MLT-HA-HPPS at 2.5 and 10 μM melittin for different time points (1, 3, 12, and 24 h) at 37 ℃, and the cells were stained with Annexin V-FITC/PI solution for 10 min. Both the DiR-BOA and Annexin V-FITC/PI fluorescence signals of the cells were analyzed using a CytoFLEX flow cytometer (Beckman Coulter, Brea, CA, USA). Data were analyzed using FlowJo software (FlowJo, LLC, Ashland, USA).

Cell proliferation assays

4T1 cells were seeded into 96-well plates (1 × 104 cells/well), and different peptide concentrations (0.312, 0.625, 1.25, 2.5, 5, 10, and 20 μM) of HA-HPPS, free melittin, and MLT-HA-HPPS were incubated with 4T1 cells for 3 h, 6 h, and 12 h at 37 ℃. The cells were washed three times with PBS to remove the drugs and further cultured at 37 °C for 21 h, 18 h, and 12 h, respectively. Cell proliferation assays were performed using CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS, Promega, G3580).

Lymph node metastasis model and fluorescence imaging

To establish the LN metastasis model of 4T1 murine breast cancer, 1 × 106 4T1 cells or tfRFP-4T1 cells in 20 μL PBS were injected into the hock area of BALB/c mice. After six days of cell inoculation, HA-HPPS and MLT-HA-HPPS (DiR-BOA: 20 nmol) were injected paracancerously into the hock area of BALB/c mice, and nanoparticles accumulation in pSLNs were detected and analyzed using a custom-made whole-body optical imaging system at 0.5 h, 3 h, 6 h, 12 h, and 24 h after injection of the probes. Fluorescence images of DiR-BOA were acquired using a NIR filter set (excitation: 716/40 nm; emission: 800/40 nm; exposure time: 20 s). For the in vivo target 4T1 cell assay, fluorescence imaging of resected pSLNs were performed at 6 h after paracancerous injection of FITC-labelled HA-HPPS and MLT-HA-HPPS. Fluorescence images of tfRFP and FITC were acquired with a filter set (excitation: 562/40 nm, emission: 640/40 nm; and excitation: 496/40 nm, emission: 562/40 nm, respectively).

In vivo SLN metastasis treatment

BALB/c mice with metastatic pSLNs were randomly divided into four groups (3–4 mice/group). Then the different groups were paracancerously injected with PBS (40 μL) or HA-HPPS, melittin, and MLT-HA-HPPS (20 nmol peptide, 40 μL) on the primary tumor after 2 days of tumor inoculation, respectively. The mice were administered the above dose once every 2 days for three times, and their primary tumor volume and body weights were measured. They were sacrificed, and their primary tumors and metastatic SLNs were weighed and collected for fluorescence images and confocal imaging on day 14 after treatment. Primary tumor volume = (length) × (width)2/2.

Statistical analysis

Statistical analysis was performed using GraphPad Prism 8 (GraphPad Software, CA). Significance of the detections and results were determined by one-way ANOVA analysis and Student’s t-test (two tailed) for the in vitro and in vivo studies. Data are presented as the mean ± standard deviation. Significant differences between or among the groups are indicated as follows: ns for no significant difference, * for P < 0.05, ** for P < 0.01, and *** for P < 0.001.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2021;71(3):209–49.

    Google Scholar 

  2. Zhou J, Yang W, Liu Q. Cancer challenges worldwide and in China: preparing for the inevitable. Sci China Life Sci. 2022;65(2):442–4.

    Article  PubMed  Google Scholar 

  3. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559–64.

    Article  CAS  PubMed  Google Scholar 

  4. Ganesh K, Massagué J. Targeting metastatic cancer. Nat Med. 2021;27(1):34–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Leong SP, Pissas A, Scarato M, Gallon F, Pissas MH, Amore M, Wu M, Faries MB, Lund AW. The lymphatic system and sentinel lymph nodes: conduit for cancer metastasis. Clin Exp Metastasis. 2022;39(1):139–57.

    Article  PubMed  Google Scholar 

  6. Brown M, Assen FP, Leithner A, Abe J, Schachner H, Asfour G, Bago-Horvath Z, Stein JV, Uhrin P, Sixt M, et al. Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice. Science. 2018;359(6382):1408–11.

    Article  CAS  PubMed  Google Scholar 

  7. Demicheli R, Retsky MW, Hrushesky WJM, Baum M, Gukas ID. The effects of surgery on tumor growth: a century of investigations. Ann Oncol. 2008;19(11):1821–8.

    Article  CAS  PubMed  Google Scholar 

  8. Ceelen W, Pattyn P, Mareel M. Surgery, wound healing, and metastasis: recent insights and clinical implications. Crit Rev Oncol Hematol. 2014;89(1):16–26.

    Article  PubMed  Google Scholar 

  9. Bello MA, Bergmann A, Dias R, Thuler LCS, Tonellotto F, Pinto RR, Fabro E. Incidence complications following sentinel lymph node biopsy or axillary lymph node dissection after breast cancer surgery. J Clin Oncol. 2012;30(27):97–97.

    Article  Google Scholar 

  10. Peng X, Wang J, Zhou F, Liu Q, Zhang Z. Nanoparticle-based approaches to target the lymphatic system for antitumor treatment. Cell Mol Life Sci. 2021;78(12):5139–61.

    Article  CAS  PubMed  Google Scholar 

  11. Fan X, Li Y, Feng Z, Chen G, Zhou J, He M, Wu L, Li S, Qian J, Lin H. Nanoprobes-assisted multichannel NIR-II fluorescence imaging-guided resection and photothermal ablation of lymph nodes. Adv Sci. 2021;8(9):2003972.

    Article  CAS  Google Scholar 

  12. Liu W, Ye X, He L, Cheng J, Luo W, Zheng M, Hu Y, Zhang W, Cao Y, Ran H, et al. A novel targeted multifunctional nanoplatform for visual chemo-hyperthermia synergy therapy on metastatic lymph nodes via lymphatic delivery. J Nanobiotechnol. 2021;19(1):432.

    Article  CAS  Google Scholar 

  13. Pang Z, Yan W, Yang J, Li Q, Guo Y, Zhou D, Jiang X. Multifunctional gold nanoclusters for effective targeting, near-infrared fluorescence imaging, diagnosis, and treatment of cancer lymphatic metastasis. ACS Nano. 2022;16(10):16019–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Tian R, Ma H, Zhu S, Lau J, Ma R, Liu Y, Lin L, Chandra S, Wang S, Zhu X, et al. Multiplexed NIR-II probes for lymph node-invaded cancer detection and imaging-guided surgery. Adv Mater. 2020;32(11):1907365.

    Article  CAS  Google Scholar 

  15. Liu J, Li H-J, Luo Y-L, Xu C-F, Du X-J, Du J-Z, Wang J. Enhanced primary tumor penetration facilitates nanoparticle draining into lymph nodes after systemic injection for tumor metastasis inhibition. ACS Nano. 2019;13(8):8648–58.

    Article  CAS  PubMed  Google Scholar 

  16. Cabral H, Makino J, Matsumoto Y, Mi P, Wu H, Nomoto T, Toh K, Yamada N, Higuchi Y, Konishi S, et al. Systemic targeting of lymph node metastasis through the blood vascular system by using size-controlled nanocarriers. ACS Nano. 2015;9(5):4957–67.

    Article  CAS  PubMed  Google Scholar 

  17. Kong X, Cheng R, Wang J, Fang Y, Hwang KC. Nanomedicines inhibiting tumor metastasis and recurrence and their clinical applications. Nano Today. 2021;36:101004.

    Article  CAS  Google Scholar 

  18. Trac N, Chung EJ. Overcoming physiological barriers by nanoparticles for intravenous drug delivery to the lymph nodes. Exp Biol Med. 2021;246(22):2358–71.

    Article  CAS  Google Scholar 

  19. Hegde M, Naliyadhara N, Unnikrishnan J, Alqahtani MS, Abbas M, Girisa S, Sethi G, Kunnumakkara AB. Nanoparticles in the diagnosis and treatment of cancer metastases: current and future perspectives. Cancer Lett. 2023;556:216066.

    Article  CAS  PubMed  Google Scholar 

  20. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science. 2002;296(5574):1883–6.

    Article  CAS  PubMed  Google Scholar 

  21. Wong SY, Hynes RO. Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide? Cell Cycle. 2006;5(8):812–7.

    Article  CAS  PubMed  Google Scholar 

  22. Liang C, Diao S, Wang C, Gong H, Liu T, Hong G, Shi X, Dai H, Liu Z. Tumor metastasis inhibition by imaging-guided photothermal therapy with single-walled carbon nanotubes. Adv Mater. 2014;26(32):5646–52.

    Article  CAS  PubMed  Google Scholar 

  23. Hu H, Wang J, Wang H, Tan T, Li J, Wang Z, Sun K, Li Y, Zhang Z. Cell-penetrating peptide-based nanovehicles potentiate lymph metastasis targeting and deep penetration for anti-metastasis therapy. Theranostics. 2018;8(13):3597–610.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Liu Z, Fan Z, Liu J, Wang J, Xu M, Li X, Xu Y, Lu Y, Han C, Zhang Z. Melittin-carrying nanoparticle suppress T cell-driven immunity in a murine allergic dermatitis model. Adv Sci. 2023;10, 2204184.

    Article  Google Scholar 

  25. Liu H, Hu Y, Sun Y, Wan C, Zhang Z, Dai X, Lin Z, He Q, Yang Z, Huang P, et al. Co-delivery of bee venom melittin and a photosensitizer with an organic-inorganic hybrid nanocarrier for photodynamic therapy and immunotherapy. ACS Nano. 2019;13(11):12638–52.

    Article  CAS  PubMed  Google Scholar 

  26. Zhang Y, Chen X, Gueydan C, Han J. Plasma membrane changes during programmed cell deaths. Cell Res. 2018;28(1):9–21.

    Article  CAS  PubMed  Google Scholar 

  27. Zhang Z, Chen J, Ding L, Jin H, Lovell JF, Corbin IR, Cao W, Lo P-C, Yang M, Tsao M-S, et al. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small. 2010;6(3):430–7.

    Article  CAS  PubMed  Google Scholar 

  28. Huang C, Jin H, Qian Y, Qi S, Luo H, Luo Q, Zhang Z. Hybrid melittin cytolytic peptide-driven ultrasmall lipid nanoparticles block melanoma growth in vivo. ACS Nano. 2013;7(7):5791–800.

    Article  CAS  PubMed  Google Scholar 

  29. Yu X, Chen L, Liu J, Dai B, Xu G, Shen G, Luo Q, Zhang Z. Immune modulation of liver sinusoidal endothelial cells by melittin nanoparticles suppresses liver metastasis. Nat Commun. 2019;10(1):574.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Yu X, Dai Y, Zhao Y, Qi S, Liu L, Lu L, Luo Q, Zhang Z. Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response. Nat Commun. 2020;11(1):1110.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Dai Y, Yu X, Wei J, Zeng F, Li Y, Yang X, Luo Q, Zhang Z. Metastatic status of sentinel lymph nodes in breast cancer determined with photoacoustic microscopy via dual-targeting nanoparticles. Light Sci Appl. 2020;9(1):164.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Ke X, Howard GP, Tang H, Cheng B, Saung MT, Santos JL, Mao H-Q. Physical and chemical profiles of nanoparticles for lymphatic targeting. Adv Drug Deliv Rev. 2019;151–152:72–93.

    Article  PubMed  Google Scholar 

  33. Louderbough JMV, Schroeder JA. Understanding the dual nature of CD44 in breast cancer progression. Mol Cancer Res. 2011;9(12):1573–86.

    Article  CAS  PubMed  Google Scholar 

  34. Tan T, Hu H, Wang H, Li J, Wang Z, Wang J, Wang S, Zhang Z, Li Y. Bioinspired lipoproteins-mediated photothermia remodels tumor stroma to improve cancer cell accessibility of second nanoparticles. Nat Commun. 2019;10(1):3322.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Ahmed M, Purushotham AD, Douek M. Novel techniques for sentinel lymph node biopsy in breast cancer: a systematic review. Lancet Oncol. 2014;15(8):e351–62.

    Article  PubMed  Google Scholar 

  36. Jeong YJ, Choi Y, Shin JM, Cho HJ, Kang JH, Park KK, Choe JY, Bae YS, Han SM, Kim CH, Chang HW, Chang YC. Melittin suppresses EGF-induced cell motility and invasion by inhibiting PI3K/Akt/mTOR signaling pathway in breast cancer cells. Food Chem Toxicol. 2014;68:218–25.

    Article  CAS  PubMed  Google Scholar 

  37. Duffy C, Sorolla A, Wang E, Golden E, Woodward E, Davern K, Ho D, Johnstone E, Pfleger K, Redfern A, et al. Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer. npj Precis Oncol. 2020;4(1):24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Trevaskis NL, Kaminskas LM, Porter CJH. From sewer to saviour—targeting the lymphatic system to promote drug exposure and activity. Nat Rev Drug Discov. 2015;14(11):781–803.

    Article  CAS  PubMed  Google Scholar 

  39. Russell PJ, Fau Hewish D, Carter T, Fau Carter T, Sterling-Levis K, Fau Sterling-Levis K, Ow K, Fau Ow K, Hattarki M, Fau Hattarki M, Doughty L, Fau Doughty L, Guthrie R, Fau Guthrie R, Shapira D, Fau Shapira D, Molloy PL, Fau Molloy Pl, Werkmeister JA, et al. Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies. Cancer Immunol Immunother. 2004;53(5):411–21.

    Article  CAS  PubMed  Google Scholar 

  40. Pan H, Fau Myerson Jw, Ivashyna O, Fau Ivashyna O, Soman NR, Fau Soman Nr, Marsh JN, Fau Marsh Jn, Hood JL, Fau Hood Jl, Lanza GM, Fau Lanza Gm, Schlesinger PH, Fau Schlesinger Ph, Wickline SA, Wickline SA. Lipid membrane editing with peptide cargo linkers in cells and synthetic nanostructures. FASEB J. 2010;24(8):2928–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Zhu W, Zhou Y, Sun D, Li Z. An uPA cleavable conjugate of a recombinant αvβ3 targeting toxin and its bioactivity. World J Microbiol Biotechnol. 2011;27:563–9.

    Article  CAS  Google Scholar 

  42. Ji C, Zhao M, Wang C, Liu R, Zhu S, Dong X, Su C, Gu Z. Biocompatible tantalum nanoparticles as radiosensitizers for enhancing therapy efficacy in primary tumor and metastatic sentinel lymph nodes. ACS Nano. 2022;16(6):9428–41.

    Article  CAS  PubMed  Google Scholar 

  43. Wu X, Wang L, Xu Y-N, Chen J-L, Luo KQ, Yuan M-H, Li J, Yuan G, Gu Z-Y, Jia X-H, et al. Chemo-phototherapy with carfilzomib-encapsulated TiN nanoshells suppressing tumor growth and lymphatic metastasis. Small. 2022;18(29):2200522.

    Article  CAS  Google Scholar 

  44. Xu M, Zhao D, Chen Y, Chen C, Zhang L, Sun L, Chen J, Tang Q, Sun S, Ma C, et al. Charge reversal polypyrrole nanocomplex-mediated gene delivery and photothermal therapy for effectively treating papillary thyroid cancer and inhibiting lymphatic metastasis. ACS Appl Mater Interfaces. 2022;14(12):14072–86.

    Article  CAS  PubMed  Google Scholar 

  45. Wang X, Dai G, Jiang G, Zhang D, Wang L, Zhang W, Chen H, Cheng T, Zhou Y, Wei X, et al. A TMVP1-modified near-infrared nanoprobe: molecular imaging for tumor metastasis in sentinel lymph node and targeted enhanced photothermal therapy. J Nanobiotechnol. 2023;21(1):130.

    Article  CAS  Google Scholar 

  46. Zhang G, Cheng W, Yang N, Yang B, Yu S, Zheng J, Li M, Fu Y, Li X, Song Y, et al. Peptide-decorated artificial erythrocyte microvesicles endowed with lymph node targeting function for drug delivery. Adv Ther. 2023;6(6):2200236.

    Article  CAS  Google Scholar 

  47. Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler IJ. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes1. Can Res. 1991;51(11):3062–6.

    CAS  Google Scholar 

  48. Lin Q, Deng D, Song X, Dai B, Yang X, Luo Q, Zhang Z. Self-assembled “off/on” nanopomegranate for in vivo photoacoustic and fluorescence imaging: strategic arrangement of kupffer cells in mouse hepatic lobules. ACS Nano. 2019;13(2):1526–37.

    CAS  PubMed  Google Scholar 

  49. Corbin IR, Chen J, Cao W, Li H, Lund-Katz S, Zheng G. Enhanced cancer-targeted delivery using engineered high-density lipoprotein-based nanocarriers. J Biomed Nanotechnol. 2007;3:367.

    Article  CAS  Google Scholar 

  50. Luo H, Yang J, Jin H, Huang C, Fu J, Yang F, Gong H, Zeng S, Luo Q, Zhang Z. Tetrameric far-red fluorescent protein as a scaffold to assemble an octavalent peptide nanoprobe for enhanced tumor targeting and intracellular uptake in vivo. FASEB J. 2011;25(6):1865–73.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the Optical Bioimaging Core Facility of WNLO-HUST and the Research Core Facilities for Life Science (HUST) for the support in data acquisition. We also thank the Analytical and Testing Center of HUST for Nanoscale Characterization & Devices (CNCD, Tecnai G2 20 U-Twin) of WNLO-HUST for facility support.

Funding

The research was supported by the National Natural Science Foundation of China (32201131), the China Postdoctoral Science Foundation (No. 2022M710990), the Hainan University Scientific Research Foundation (KYQD(ZR)20078), 111 Project (D22022), the Innovation Fund of WNLO.

Author information

Authors and Affiliations

  1. State Key Laboratory of Digital Medical Engineering, School of Biomedical Engineering, Hainan University, Haikou, 570228, Hainan, China

    Yanfeng Dai, Xiang Yu, Xingzhou Peng & Zhihong Zhang

  2. Britton Chance Center and MoE Key Laboratory for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology, Wuhan, 430074, Hubei, China

    Yuehong Leng, Junjie Wang, Yifan Zhao & Zhihong Zhang

  3. Princess Margaret Cancer Centre, University Health Network, 101 College Street, Toronto, Canada

    Juan Chen

Authors
  1. Yanfeng Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiang Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuehong Leng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xingzhou Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Junjie Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yifan Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Juan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zhihong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

DY and ZZ conceived the idea and designed the experiments; DY, YX, LY, PX, WJ and ZY performed the experiments. DY, YX, and CJ drafted and revised the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Zhihong Zhang.

Ethics declarations

Ethics approval and consent to participate

The Huazhong University of Science & Technology Institutional Animal Care and Use Committee gave its permission to all procedures involving experimental animals.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests, financial or otherwise.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1

: Fig. S1 In vitro evaluation of the stability of MLT-HA-HPPS. (a) The photographs of MLT-HA-HPPS hydrate before and after lyophilization and rehydration. (b) The change in size and zeta potential of the MLT-HA-HPPS hydrate and rehydration. (c) SDS-PAGE and fluorescence imaging to evaluate the stability of MLT-HA-HPPS after 12 h and 24 h of incubation at 37 °C. Green: FITC; Red: DiR-BOA. Fig. S2 UV–vis absorption spectrums of MLT-HA-HPPS, HA-HPPS, and free melittin in PBS solution at room temperature. Fig. S3 Proliferation assays to evaluate the cytotoxicity of melittin, MLT-HA-HPPS, and HA-HPPS on 4T1 cells after 6 h and 12 h of incubation. Data are presented as the means ± SD, n = 3. Fig. S4 Confocal imaging verified that the MLT-HA-HPPS and HA-HPPS are mainly taken up by APCs. After footpad injection of nanoparticles for 24 h, the normal PLNs were removed for immunofluorescence imaging. Macrophage: FITC-F4/80+, DC: FITC-CD11c+. Fig. S5 Evaluation of the biosafety of nanoparticles in vivo. (a) Biochemical analysis of liver and kidney function of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (T-Bil), and blood urea nitrogen (BUN) (n = 3 per group). (b) Histopathological analysis of H&E-stained organ sections from the hearts, livers, spleens, lungs, kidneys, brains, and iPLNs after 24 h and 48 h of HA-HPPS and MLT-HA-HPPS injection. Scale bar: 50 μm. Fig. S6 Release profile of peptide from MLT-HA-HPPS using dialysis.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dai, Y., Yu, X., Leng, Y. et al. Effective treatment of metastatic sentinel lymph nodes by dual-targeting melittin nanoparticles. J Nanobiotechnol 21, 245 (2023). https://doi.org/10.1186/s12951-023-02026-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12951-023-02026-7

Keywords

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us